Zacks Investment Research upgraded shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a buy rating in a research note released on Saturday, Zacks.com reports. They currently have $18.00 price target on the stock.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
Several other equities analysts have also recently weighed in on the company. Leerink Swann set a $27.00 price target on Kura Oncology and gave the company a buy rating in a research report on Saturday, June 15th. Deutsche Bank assumed coverage on Kura Oncology in a research report on Thursday, July 18th. They issued a buy rating and a $28.00 price target for the company. Citigroup lifted their price target on Kura Oncology from $18.00 to $25.00 and gave the company a buy rating in a research report on Friday, May 24th. HC Wainwright reiterated a buy rating and issued a $29.00 price target on shares of Kura Oncology in a research report on Friday, August 2nd. Finally, BidaskClub cut Kura Oncology from a sell rating to a strong sell rating in a research report on Wednesday, September 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $27.10.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.38) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.03. On average, sell-side analysts predict that Kura Oncology will post -1.61 EPS for the current year.
In related news, insider Antonio Gualberto sold 18,000 shares of the business’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $21.11, for a total transaction of $379,980.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 11.00% of the stock is owned by insiders.
A number of institutional investors have recently bought and sold shares of the stock. Meeder Asset Management Inc. grew its position in Kura Oncology by 164.9% during the second quarter. Meeder Asset Management Inc. now owns 1,934 shares of the company’s stock worth $38,000 after buying an additional 1,204 shares in the last quarter. Point72 Hong Kong Ltd purchased a new position in shares of Kura Oncology in the 2nd quarter worth about $25,000. Wells Fargo & Company MN boosted its holdings in shares of Kura Oncology by 3.3% in the 2nd quarter. Wells Fargo & Company MN now owns 42,448 shares of the company’s stock worth $835,000 after purchasing an additional 1,346 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in shares of Kura Oncology by 22.4% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 12,000 shares of the company’s stock worth $235,000 after purchasing an additional 2,200 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Kura Oncology by 599.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,824 shares of the company’s stock worth $56,000 after purchasing an additional 2,420 shares in the last quarter. Institutional investors and hedge funds own 85.47% of the company’s stock.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Further Reading: Return on Investment (ROI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.